Please login to the form below
duloxetine
This page shows the latest duloxetine news and features for those working in and with pharma, biotech and healthcare.
Lilly mulls divestment of its animal health operations
Alimta (pemetrexed) and antidepressant Cymbalta (duloxetine) resulting from generic competition.
Latest news
-
Daiichi drug hits mark in shingles pain, but misses in other indications
At the moment, there are just three approved drugs for fibromyalgia - Lyrica, Eli Lilly's Cymbalta (duloxetine) and Allergan's Savella (milnacipran) - and while these have been shown to reduce pain
-
Lilly’s president and chief executive John Lechleiter to retire
raloxifene) and antidepressant Cymbalta (duloxetine) have also expired.
-
UK court backs Actavis in dispute over Lilly's Alimta
Maintaining Alimta's revenue stream is a priority for Lilly as it weathers the loss of patent protection for other brands, including osteoporosis drug Evista (raloxifene) and antidepressant Cymbalta (duloxetine) and
-
Lilly and AZ forge closer immuno-oncology bond
A 33% increase in animal health revenue - thanks to Lily's recent acquisition of Novartis' veterinary franchise - also helped to offset sharp drops in sales of antidepressant Cymbalta (duloxetine) and Evista
-
US filing aims to elevate Brintellix above its competition
The new filing is based in part on the results of the CONNECT trial, which found that Brintellix performed better than Eli Lilly's rival antidepressant Cymbalta (duloxetine) on various cognitive
More from news
Approximately 3 fully matching, plus 42 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
